Monitor the stockholder vote on the merger and CVR proposal; the equity commitment provides a backstop but only if the merger closes. The additional convertible notes add near-term dilution risk. Failure to close the merger or obtain Nasdaq compliance could trigger default and accelerate the 200% redemption premium.
Price Chart
Executive Summary
Senti Biosciences issued an additional $2.0M in Senior Secured Convertible Notes to NSG BioInnovation Fund and secured a $2.5M equity commitment from a Celadon affiliate, conditioned on the closing of its pending merger and Nasdaq compliance. The company is raising small-scale, distressed capital to fund operations and support the merger process, while a potential CVR of up to $60M tied to SENTI-202 milestones remains contingent on stockholder approval.
Key Facts
- Issued $2.0M aggregate principal of Senior Secured Convertible Notes to NSG BioInnovation Fund on September 3, 2026
- Entered equity commitment letter with CPIF II-9 Limited (Celadon affiliate) for $2.5M of common stock at Nasdaq Minimum Price, contingent on merger closing
- Merger Agreement dated July 14, 2026; Celadon affiliate to merge with Senti Holdings and issue CVR worth up to $60M based on SENTI-202 milestones
- Company must retain at least $600K cash post-closing and submit Nasdaq compliance plan as conditions to equity commitment
Financial Impact
Additional $2.0M convertible debt (senior secured, 200% principal at maturity, 12% default interest) and $2.5M equity at minimum price; combined $4.5M gross proceeds, but highly dilutive given $11M market cap
Risk Factors
- Merger may not close by December 31, 2026 outside date, terminating equity commitment
- Nasdaq compliance plan may not be accepted, jeopardizing continued listing
- Additional convertible notes increase debt and potential dilution; 200% redemption premium on default is punitive
- CVR milestone payments are contingent on regulatory and sales achievements for SENTI-202, which is early-stage
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-060600 |
| Exhibit: ex102_equitycommitmentlett.htm | 0001628280-26-060600 |
| Document: snti-20260903.htm | 0001628280-26-060600 |
| Document: 0001628280-26-060600-index-headers.html | 0001628280-26-060600 |
| Document: 0001628280-26-060600-index.html | 0001628280-26-060600 |
| Document: 0001628280-26-060600.txt | 0001628280-26-060600 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.1720 | awaiting T+5 | — | $0.1750 (−1.74%) |
Oct 13, 2026 13d ago | DEFA14A | $0.2408 $0.2175 | ▼ −9.68% | ▼ −10.13% | $0.1750 (−27.33%) |
Oct 13, 2026 13d ago | 8-K | $0.2408 $0.2175 | ▲ +9.68% | ▲ +10.13% | $0.1750 (+27.33%) |
Sep 25, 2026 4w ago | EFFECT | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1750 (+46.86%) |
Sep 24, 2026 4w ago | DEFM14A | $0.3293 $0.3223 | ▲ +2.13% | ▲ +1.90% | $0.1750 (+46.86%) |
Sep 22, 2026 5w ago | S-3/A | $0.3156 $0.3075 | ▲ +2.57% | ▲ +1.38% | $0.1750 (+44.55%) |
Sep 10, 2026 6w ago | S-3/A | $0.3060 $0.3200 | ▼ −4.58% | ▼ −4.80% | $0.1750 (+42.81%) |
Sep 4, 2026 7w ago | DEFA14A | $0.3326 $0.3021 | ▼ −9.17% | ▼ −7.96% | $0.1750 (−47.38%) |
Sep 4, 2026 7w ago | 8-K | $0.3326 $0.3021 | ▲ +9.17% | ▲ +7.96% | $0.1750 (+47.38%) |
Aug 20, 2026 9w ago | 8-K | $0.3886 $0.3770 | ▲ +2.99% | ▲ +3.46% | $0.1750 (+54.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers